Cargando…
Latest developments in MUC1 immunotherapy
Currently, there is renewed interest in attempting to recruit the host immune system to eliminate cancers, and within this renewed activity, MUC1 continues to arouse interest. MUC1 has been considered a possible therapeutic target for the past 30 years as it is up-regulated, aberrantly glycosylated...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008591/ https://www.ncbi.nlm.nih.gov/pubmed/29784646 http://dx.doi.org/10.1042/BST20170400 |
_version_ | 1783333210971701248 |
---|---|
author | Taylor-Papadimitriou, Joyce Burchell, Joy M. Graham, Rosalind Beatson, Richard |
author_facet | Taylor-Papadimitriou, Joyce Burchell, Joy M. Graham, Rosalind Beatson, Richard |
author_sort | Taylor-Papadimitriou, Joyce |
collection | PubMed |
description | Currently, there is renewed interest in attempting to recruit the host immune system to eliminate cancers, and within this renewed activity, MUC1 continues to arouse interest. MUC1 has been considered a possible therapeutic target for the past 30 years as it is up-regulated, aberrantly glycosylated and its polarization is lost in many adenocarcinomas. Moreover, MUC1 is expressed by some haematopoietic cancers, including acute myeloid leukaemia and myeloma. Although multiple clinical trials have been initiated and immune responses have been documented, effective clinical benefit worthy of approval for general application has not as yet been achieved. However, this does not appear to have quelled the interest in MUC1 as a therapeutic target, as shown by the increase in the number of MUC1-based clinical trials initiated in 2017 ( Figure 1). As with all translational studies, incorporating new relevant research findings into therapeutic strategy is difficult. Decisions are made to commit to a specific strategy based on the information and data available when the trial is initiated. However, the time required for preclinical studies and early trials can render the founding concept not always appropriate for proceeding to a larger definitive trial. Here, we summarize the attempts made, to date, to bring MUC1 into the world of cancer immunotherapy and discuss how research findings regarding MUC1 structure and function together with expanded knowledge of its interactions with the tumour environment and immune effector cells could lead to improved therapeutic approaches. |
format | Online Article Text |
id | pubmed-6008591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60085912018-07-05 Latest developments in MUC1 immunotherapy Taylor-Papadimitriou, Joyce Burchell, Joy M. Graham, Rosalind Beatson, Richard Biochem Soc Trans Review Articles Currently, there is renewed interest in attempting to recruit the host immune system to eliminate cancers, and within this renewed activity, MUC1 continues to arouse interest. MUC1 has been considered a possible therapeutic target for the past 30 years as it is up-regulated, aberrantly glycosylated and its polarization is lost in many adenocarcinomas. Moreover, MUC1 is expressed by some haematopoietic cancers, including acute myeloid leukaemia and myeloma. Although multiple clinical trials have been initiated and immune responses have been documented, effective clinical benefit worthy of approval for general application has not as yet been achieved. However, this does not appear to have quelled the interest in MUC1 as a therapeutic target, as shown by the increase in the number of MUC1-based clinical trials initiated in 2017 ( Figure 1). As with all translational studies, incorporating new relevant research findings into therapeutic strategy is difficult. Decisions are made to commit to a specific strategy based on the information and data available when the trial is initiated. However, the time required for preclinical studies and early trials can render the founding concept not always appropriate for proceeding to a larger definitive trial. Here, we summarize the attempts made, to date, to bring MUC1 into the world of cancer immunotherapy and discuss how research findings regarding MUC1 structure and function together with expanded knowledge of its interactions with the tumour environment and immune effector cells could lead to improved therapeutic approaches. Portland Press Ltd. 2018-06-19 2018-05-21 /pmc/articles/PMC6008591/ /pubmed/29784646 http://dx.doi.org/10.1042/BST20170400 Text en © 2018 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Articles Taylor-Papadimitriou, Joyce Burchell, Joy M. Graham, Rosalind Beatson, Richard Latest developments in MUC1 immunotherapy |
title | Latest developments in MUC1 immunotherapy |
title_full | Latest developments in MUC1 immunotherapy |
title_fullStr | Latest developments in MUC1 immunotherapy |
title_full_unstemmed | Latest developments in MUC1 immunotherapy |
title_short | Latest developments in MUC1 immunotherapy |
title_sort | latest developments in muc1 immunotherapy |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008591/ https://www.ncbi.nlm.nih.gov/pubmed/29784646 http://dx.doi.org/10.1042/BST20170400 |
work_keys_str_mv | AT taylorpapadimitrioujoyce latestdevelopmentsinmuc1immunotherapy AT burchelljoym latestdevelopmentsinmuc1immunotherapy AT grahamrosalind latestdevelopmentsinmuc1immunotherapy AT beatsonrichard latestdevelopmentsinmuc1immunotherapy |